CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months

Loading news article.

CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months | WAPE

CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months

Article summary

Related companies

Comments —